Literature DB >> 24199757

Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.

Min Jae Cha1, Ho Yun Lee2, Kyung Soo Lee1, Ji Yun Jeong3, Joungho Han3, Young Mog Shim4, Hye Sun Hwang1.   

Abstract

OBJECTIVE: To evaluate the clinical effect of the presence of a micropapillary or solid subtype on the outcomes in lung adenocarcinoma and to determine the predictors of such a histopathologic diagnosis.
METHODS: A total of 511 patients with lung adenocarcinoma ≤3 cm were included. According to the presence of micropapillary or solid subtypes, we classified the patients into 4 subgroups: both subtypes absent (MP-/S-, n = 87), either subtype present (MP+/S-, n = 207 and MP-/S+, n = 196), and both present (MP+/S+, n = 21) to determine the association between the micropapillary or solid subtype and survival outcome or clinical and imaging conditions. Univariate and multivariate analyses were undertaken to determine the parameters, allowing the prediction of the presence of the micropapillary or solid subtype.
RESULTS: Overall survival (OS) and disease-free survival (DFS) differed significantly among the 4 subgroups (P < .001 and P = .004, respectively). The MP-/S- tumors showed better DFS than those containing either the micropapillary or solid subtype. Patients with the micropapillary subtype had significantly worse OS than patients without the micropapillary subtype. This difference remained significant, together with stage, after adjustment for gender, age, adjuvant therapy, tumor size, and solid subtype (DFS and OS, P = .016 and P = .002, respectively). On multivariate analysis, greater than stage I, tumor size ≥2.5 cm, solid mass, and maximal standardized uptake value of ≥7 were independent predictors of the presence of a micropapillary or solid subtype.
CONCLUSIONS: Micropapillary and solid subtypes are common in tumors greater than stage I, with size ≥2.5 cm, pure solid type, and maximal standardized uptake value of ≥7, which were predictors for poor DFS. The presence of the micropapillary subtype was a single prognostic factor for OS.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24199757     DOI: 10.1016/j.jtcvs.2013.09.045

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  54 in total

1.  Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Authors:  Song Gao; Seth Stein; Elena N Petre; Waleed Shady; Jeremy C Durack; Carole Ridge; Prasad Adusumilli; Natasha Rekhtman; Stephen B Solomon; Etay Ziv
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

2.  Prediction of micropapillary and solid pattern in lung adenocarcinoma using radiomic values extracted from near-pure histopathological subtypes.

Authors:  Li-Wei Chen; Shun-Mao Yang; Hao-Jen Wang; Yi-Chang Chen; Mong-Wei Lin; Min-Shu Hsieh; Hsiang-Lin Song; Huan-Jang Ko; Chung-Ming Chen; Yeun-Chung Chang
Journal:  Eur Radiol       Date:  2021-01-03       Impact factor: 5.315

Review 3.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  Taking the measure of lung adenocarcinoma: towards a quantitative approach to tumor spread through air spaces (STAS).

Authors:  Vicente Morales-Oyarvide; Mari Mino-Kenudson
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Micropapillary histological subtype in lung adenocarcinoma of 2 cm or less: impact on recurrence and clinical predictors.

Authors:  Yukihiro Yoshida; Jun-Ichi Nitadori; Aya Shinozaki-Ushiku; Jiro Sato; Tempei Miyaji; Takuhiro Yamaguchi; Masashi Fukayama; Jun Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-02-27

6.  Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates.

Authors:  Shanyuan Zhang; Shaolei Li; Yuquan Pei; Miao Huang; Fangliang Lu; Qingfeng Zheng; Nan Li; Yue Yang
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

7.  The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.

Authors:  Takashi Eguchi; Kyuichi Kadota; Bernard J Park; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

8.  Significance of nonmucinous lepidic component with mild nuclear atypia in the discrimination of multiple primary lung cancers from intrapulmonary metastases.

Authors:  Wei Sun; Yu Liu; Xiang-Yang Liu; Dong-Mei Lin; Ning Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

9.  Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.

Authors:  Yang Qu; Dan Zhao; Jing Mu; Nanying Che; Chen Zhang; Zichen Liu; Dan Su; Lijuan Zhou; Haiqing Zhang; Lixin Wei
Journal:  Tumour Biol       Date:  2015-08-09

Review 10.  Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

Authors:  Jody C Chuang; Joseph B Shrager; Heather A Wakelee; Joel W Neal
Journal:  Clin Ther       Date:  2016-06-29       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.